Medicure Reports Financial Results for Quarter Ended September 30, 2026 and Schedules November 23, 2026 Conference Call
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Medicure (MCUJF) reported net revenue fell to C$7.9 million for the quarter ended September 30, 2026. Revenue was C$8.2 million a year earlier. Net loss narrowed to C$1.3 million from C$1.4 million, with loss per share unchanged at C$0.13. Adjusted EBITDA loss widened to C$820,000 from C$597,000. Adjusted EBITDA excludes interest, taxes, depreciation and amortization and adjusts for noncash and nonrecurring items.
Pharmacy segment revenue fell to C$6.1 million from C$6.4 million, despite higher sales at Marley Drug. Unrestricted cash fell to C$1.1 million at September 30, 2026, from C$3.8 million at December 31, 2025. Nine-month net revenue rose to C$23.28 million from C$20.312 million, while net loss widened to C$3.157 million from C$2.876 million. A results call is scheduled for November 23, 2026, at 8:30 a.m. Eastern Time.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQuarterly net loss narrowed to C$1.3 million from C$1.4 million a year earlier; loss per share stayed at C$0.13.
- Moderate pointNine-month net revenue rose to C$23.28 million from C$20.312 million a year earlier.
- Minor pointNine-month gross profit rose to C$9.299 million from C$9.051 million a year earlier.
- Minor pointMarley Drug quarterly net revenue rose to C$3.5 million from C$3.3 million a year earlier.
- Minor pointQuarterly ZYPITAMAG revenue stayed at C$1.7 million on a rounded basis, with increases through insured channels and Marley Drug.
6 minor points
- Minor pointReported quarterly cost of goods sold fell to C$5.326 million from C$5.386 million a year earlier.
- Minor pointQuarterly general and administrative expenses fell to C$1.038 million from C$1.167 million a year earlier.
- Minor pointQuarterly selling expenses fell to C$2.137 million from C$2.199 million a year earlier.
- Minor pointQuarterly research and development expenses fell to C$676,000 from C$717,000 a year earlier.
- Minor pointTotal liabilities fell to C$10.813 million at September 30, 2026, from C$12.04 million at December 31, 2025.
- Minor pointNine-month investing cash outflow fell to C$388,000 from C$2.177 million a year earlier.
Negative
- Moderate pointQuarterly net revenue fell to C$7.9 million from C$8.2 million a year earlier.
- Moderate pointUnrestricted cash fell to C$1.1 million at September 30, 2026, from C$3.8 million at December 31, 2025.
- Moderate pointQuarterly adjusted EBITDA loss widened to C$820,000 from C$597,000 a year earlier.
- Moderate pointNine-month operating cash outflow rose to C$2.076 million from C$592,000 a year earlier.
- Moderate pointNine-month net loss widened to C$3.157 million, or C$0.30 per share, from C$2.876 million, or C$0.28 per share.
- Moderate pointQuarterly gross profit fell to C$2.58 million from C$2.773 million a year earlier.
- Moderate pointNine-month cost of goods sold rose to C$13.981 million from C$11.261 million a year earlier.
- Moderate pointShareholders’ equity fell to C$10.195 million at September 30, 2026, from C$12.909 million at December 31, 2025.
7 minor points
- Minor pointPharmacy segment quarterly net revenue fell to C$6.1 million from C$6.4 million a year earlier.
- Minor pointWest Olympia Pharmacy quarterly net revenue fell to C$2.0 million from C$2.2 million a year earlier.
- Minor pointGateway Pharmacy quarterly net revenue fell to C$739,000 from C$890,000 a year earlier.
- Minor pointQuarterly AGGRASTAT net sales fell to C$979,000 from C$1.0 million a year earlier.
- Minor pointNine-month selling expenses rose to C$6.848 million from C$6.161 million a year earlier.
- Minor pointNine-month research and development expenses rose to C$2.139 million from C$2.028 million a year earlier.
- Minor pointQuarterly noncash amortization of assets from the ZYPITAMAG and pharmacy purchases added C$669,000 to the net loss.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WINNIPEG, MB / ACCESS Newswire / November 19, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC Pink:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended September 30, 2026 and will have a conference call to present the Financial Results on November 23, 2026 at 8:30 am Eastern Time.
Quarter Ended September 30, 2026 Highlights:
- Recorded total net revenue of
$7.9 million during the period ended September 30, 2026, compared to$8.2 million for the period ended September 30, 2025; - Recorded total net revenue from the sale of ZYPITAMAG®of
$1.7 million ($781,000 through the traditional insured channels, and$930,000 through Marley Drug) during the quarter ended September 30, 2026, compared to$1.7 million ($769,000 through the traditional insured channels, and$917,000 through Marley Drug) for the quarter ended September 30, 2025; - Recorded total net revenue from the sale of AGGRASTAT® of
$979,000 during the quarter ended September 30, 2026, compared to$1.0 million during the quarter ended September 30, 2025; - The Pharmacy Business Segment, which includes Marley Drug, and the Company's two 2025 acquired pharmacies, Gateway Medical Pharmacy and West Olympia Pharmacy, recorded total net revenue of
$6.1 million ($930,000 from sales of ZYPITAMAG®, and$5.2 million from other pharmacy revenue) during the quarter ended September 30, 2026, compared to net revenue of$6.4 million ($917,000 from sales of ZYPITAMAG®, and$5.4 million from other pharmacy revenue) during the quarter ended September 30, 2025; - Medicure invested
$676,000 in research and development during the quarter ended September 30, 2026, underscoring our commitment to advancing innovative therapies, such as the Phase 3 trial of the Company's investigational product MC-1 for the treatment of PNPO deficiency and delivering long-term value to patients and shareholders; - Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended September 30, 2026 was negative
$820,000 , compared to negative adjusted EBITDA of$597,000 for the quarter ended September 30, 2025 and; - Net loss for the quarter ended September 30, 2026 was
$1.3 million or$0.13 per share, compared to a net loss of$1.4 million or$0.13 per share for the quarter ended September 30, 2025; the net loss includes non-cash expenses of$669,000 relating to amortization of the assets relating to the purchase of ZYPITAMAG® and the Pharmacy Business Segment.
Financial Results
Marley Drug recorded net revenue of
West Olympia Pharmacy and Gateway Pharmacy, both acquired in the first half of 2025, contributed net revenue of
ZYPITAMAG through insured channels contributed
Net AGGRASTAT® product sales for the quarter ended September 30, 2026 were
Research and development expenditures for the quarter ended September 30, 2026 totaled
Adjusted EBITDA for the quarter ended September 30, 2026 was negative
Net loss for the quarter ended September 30, 2026 was
At September 30, 2026, the Company had unrestricted cash totaling
All amounts referenced herein are in Canadian dollars unless otherwise noted.
The full financial statements are available at www.sedarplus.ca and on the Company's website at www.medicure.com.
Notes
- The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EBITDA as "EBITDA adjusted for non‑cash and non-recurring items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three month period ended September 30, 2026 and 2025 results prepared using IFRS, do not have any standardized meaning according to IFRS. It is therefore unlikely to be comparable to similar measures presented by other companies.
Conference Call Info:
Topic: Medicure's Financial Results for the Quarter Ended September 30, 2026
Call date: Monday, November 23, 2026
Time: 8:30 AM Eastern Time (8:30 AM Manitoba Time)
Toll Free: 1 (877) 545-0320
International: 1 (973) 528-0002
Participant Access Code: 476389
Webcast: This conference call will be webcast live over the internet at the following link: https://www.webcaster5.com/Webcast/Page/2965/54875
About Medicure Inc.
Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc. ("Marley Drug"), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery. Medicure also operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near major transportation lines and multiple healthcare clinics and centers. In addition to regular customers, the pharmacy services multiple long-term care facilities and provides non-sterile compounding services. Medicure also operates West Olympia Pharmacy, located in Olympia, Washington in a medical office complex near multiple clinics. For more information visit www.marleydrug.com. For more information about Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, please visit www.aggrastat.com or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit www.zypitamag.com or refer to the full Prescribing Information.
To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F.
AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks.
For more information, please contact:
Dr. Albert D. Friesen
Chief Executive Officer
Tel. 888-435-2220
Fax 204-488-9823
E-mail: info@medicure.com
www.medicure.com
Condensed Consolidated Interim Statements of Financial Position
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)
| September 30, 2026 | December 31, 2025 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 1,077 | $ | 3,835 | ||||
Accounts receivable | 5,152 | 4,817 | ||||||
Inventories | 2,805 | 2,942 | ||||||
Prepaid expenses | 215 | 293 | ||||||
Total current assets | 9,249 | 11,887 | ||||||
Non-current assets: | ||||||||
Property and equipment | 897 | 945 | ||||||
Intangible assets | 6,340 | 7,748 | ||||||
Goodwill | 4,410 | 4,260 | ||||||
Other assets | 112 | 109 | ||||||
Total non-current assets | 11,759 | 13,062 | ||||||
Total assets | $ | 21,008 | $ | 24,949 | ||||
Liabilities and Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable and accrued liabilities | $ | 9,959 | $ | 10,587 | ||||
Income taxes payable | 6 | 90 | ||||||
Current portion of lease obligations | 437 | 464 | ||||||
Acquisition payable | - | 388 | ||||||
Holdback payable | - | 84 | ||||||
Total current liabilities | 10,402 | 11,613 | ||||||
Non-current liabilities | ||||||||
Lease obligations | 411 | 427 | ||||||
Total non-current liabilities | 411 | 427 | ||||||
Total liabilities | 10,813 | 12,040 | ||||||
Equity: | ||||||||
Share capital | 81,014 | 81,014 | ||||||
Contributed surplus | 11,048 | 11,055 | ||||||
Accumulated other comprehensive loss | (4,722 | ) | (5,172 | ) | ||||
Deficit | (77,145 | ) | (73,988 | ) | ||||
Total equity | 10,195 | 12,909 | ||||||
Total liabilities and equity | $ | 21,008 | $ | 24,949 | ||||
Condensed Consolidated Interim Statements of Net Loss and Comprehensive Loss
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)
| For the three months ended September 30 | For the nine months ended September 30 | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Revenue, net | $ | 7,906 | $ | 8,159 | $ | 23,280 | $ | 20,312 | ||||||||
Cost of goods sold | 5,326 | 5,386 | 13,981 | 11,261 | ||||||||||||
Gross profit | 2,580 | 2,773 | 9,299 | 9,051 | ||||||||||||
Expenses | ||||||||||||||||
Selling | 2,137 | 2,199 | 6,848 | 6,161 | ||||||||||||
General and administrative | 1,038 | 1,167 | 3,303 | 3,526 | ||||||||||||
Research and development | 676 | 717 | 2,139 | 2,028 | ||||||||||||
| 3,851 | 4,083 | 12,290 | 11,715 | |||||||||||||
Finance costs (income): | ||||||||||||||||
Finance expense (income), net | 15 | 2 | 44 | (52 | ) | |||||||||||
Foreign exchange loss, net | 29 | 21 | 56 | 105 | ||||||||||||
| 44 | 23 | 100 | 53 | |||||||||||||
Net loss before income taxes | $ | (1,315 | ) | $ | (1,333 | ) | $ | (3,091 | ) | $ | (2,717 | ) | ||||
Income tax expense | ||||||||||||||||
Current | 8 | 63 | 66 | 159 | ||||||||||||
Net loss | $ | (1,323 | ) | $ | (1,396 | ) | $ | (3,157 | ) | $ | (2,876 | ) | ||||
Other comprehensive income: | ||||||||||||||||
Item that may be reclassified to profit or loss | ||||||||||||||||
Exchange differences on translation of foreign subsidiaries | (51 | ) | 362 | 450 | (695 | ) | ||||||||||
Other comprehensive income (loss), net of tax | (51 | ) | 362 | 450 | (695 | ) | ||||||||||
Comprehensive loss | $ | (1,374 | ) | $ | (1,034 | ) | $ | (2,707 | ) | $ | (3,571 | ) | ||||
Loss per share | ||||||||||||||||
Basic | $ | (0.13 | ) | $ | (0.13 | ) | $ | (0.30 | ) | $ | (0.28 | ) | ||||
Diluted | $ | (0.13 | ) | $ | (0.13 | ) | $ | (0.30 | ) | $ | (0.28 | ) | ||||
Condensed Consolidated Interim Statements of Cash Flows
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)
For the nine months ended September 30 | 2026 | 2025 | ||||||
Cash (used in) provided by: | ||||||||
Operating activities: | ||||||||
Net loss for the period | $ | (3,157 | ) | $ | (2,876 | ) | ||
Adjustments for: | ||||||||
Amortization of property, plant and equipment | 338 | 373 | ||||||
Amortization of intangible assets | 1,640 | 1,594 | ||||||
Share-based compensation | (7 | ) | 101 | |||||
Inventory recovery, net | (212 | ) | - | |||||
Finance expense (income), net | 44 | (52 | ) | |||||
Unrealized foreign exchange loss | 56 | 105 | ||||||
Income tax expense | 66 | 159 | ||||||
Change in the following: | ||||||||
Accounts receivable | (244 | ) | 819 | |||||
Inventories | 434 | (524 | ) | |||||
Prepaid expenses | 83 | (128 | ) | |||||
Accounts payable and accrued liabilities | (963 | ) | (28 | ) | ||||
Interest (paid) received, net | (4 | ) | 109 | |||||
Income taxes paid | (150 | ) | (244 | ) | ||||
Cash used in operating activities | (2,076 | ) | (592 | ) | ||||
Investing activities: | ||||||||
Acquisition of Gateway Pharmacy | (388 | ) | (542 | ) | ||||
Acquisition of West Olympia Pharmacy | - | (1,635 | ) | |||||
Cash flows used in investing activities | (388 | ) | (2,177 | ) | ||||
Financing activities: | ||||||||
Lease payments | (324 | ) | (304 | ) | ||||
Cash flows used in financing activities | (324 | ) | (304 | ) | ||||
Foreign exchange gain on cash held in foreign currency | 30 | - | ||||||
Decrease in cash and cash equivalents | (2,758 | ) | (3,073 | ) | ||||
Cash and cash equivalents, beginning of period | 3,835 | 7,191 | ||||||
Cash and cash equivalents, end of period | $ | 1,077 | $ | 4,118 | ||||
SOURCE: Medicure, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.